FBB
VRTX icon

Fulton Breakefield Broenniman’s Vertex Pharmaceuticals VRTX Stock Holding History

Fulton Breakefield Broenniman’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-2,679
Closed -$729K – 170
2020
Q3 		$729K Sell
2,679
-41
-2% -$11.3K 0.08% 84
2020
Q2 		$790K Buy
2,720
+24
+0.9% +$6.51K 0.1% 81
2020
Q1 		$642K Buy
2,696
+45
+2% +$10.3K 0.1% 83
2019
Q4 		$580K Buy
2,651
+315
+13% +$63.8K 0.07% 105
2019
Q3 		$396K Buy
+2,336
New +$413K 0.05% 120

Other funds holding VRTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Fulton Breakefield Broenniman's VRTX Position: Q4 2020 in Review

Fulton Breakefield Broenniman sold out of Vertex Pharmaceuticals (VRTX) in Q4 2020, closing a stake of 2,679 shares — an estimated $729K sold.

Fulton Breakefield Broenniman first reported a position in VRTX in Q3 2019 and held it in 5 quarters. The position peaked at $790K in Q2 2020. 971 funds tracked by Wall St. Rank hold VRTX as of Q4 2020.

  • Fulton Breakefield Broenniman reported no remaining Vertex Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
  • Fulton Breakefield Broenniman sold 2,679 Vertex Pharmaceuticals shares in Q4 2020, an estimated $729K.
  • Fulton Breakefield Broenniman first reported a position in Vertex Pharmaceuticals in Q3 2019 and held it in 5 quarters.
  • Fulton Breakefield Broenniman's Vertex Pharmaceuticals position peaked at $790K in Q2 2020.
  • 971 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2020.

Based on Fulton Breakefield Broenniman's 13F filing for Q4 2020, filed 14 Jan 2021.